However, the pathogenic variants of BRCA1/2 or other forms of HRD make cancer cells particularly sensitive to PARPi, the mechanism is called synthetic lethality, and the concurrent loss of both repair pathways leads to cell death. Here, BRCA1 is linked to cancer.